STRO Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals has a net margin of -436.62% compared to Sutro Biopharma's net margin of -49.65%. Sutro Biopharma's return on equity of -322.47% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Sutro Biopharma has a consensus price target of $3.26, signalling upside risk potential of 307.65%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 41.67%. Given that Sutro Biopharma has higher upside potential than NovaBay Pharmaceuticals, analysts believe Sutro Biopharma is more attractive than NovaBay Pharmaceuticals.

Sutro Biopharma has a beta of 1.699, which suggesting that the stock is 69.868% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.427, suggesting its less volatile than the S&P 500 by 57.305%.

Sutro Biopharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sutro Biopharma pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Sutro Biopharma quarterly revenues are $17.4M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Sutro Biopharma's net income of -$76M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Sutro Biopharma's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sutro Biopharma is 0.99x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Nanoviricides has a net margin of -436.62% compared to Sutro Biopharma's net margin of --. Sutro Biopharma's return on equity of -322.47% beat Nanoviricides's return on equity of --.

Sutro Biopharma has a consensus price target of $3.26, signalling upside risk potential of 307.65%. On the other hand Nanoviricides has an analysts' consensus of -- which suggests that it could grow by 428.46%. Given that Nanoviricides has higher upside potential than Sutro Biopharma, analysts believe Nanoviricides is more attractive than Sutro Biopharma.

Sutro Biopharma has a beta of 1.699, which suggesting that the stock is 69.868% more volatile than S&P 500. In comparison Nanoviricides has a beta of 0.913, suggesting its less volatile than the S&P 500 by 8.749%.

Sutro Biopharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nanoviricides offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sutro Biopharma pays -- of its earnings as a dividend. Nanoviricides pays out -- of its earnings as a dividend.

Sutro Biopharma quarterly revenues are $17.4M, which are larger than Nanoviricides quarterly revenues of --. Sutro Biopharma's net income of -$76M is lower than Nanoviricides's net income of -$2.2M. Notably, Sutro Biopharma's price-to-earnings ratio is -- while Nanoviricides's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sutro Biopharma is 0.99x versus -- for Nanoviricides. Usually stocks with elevated PS ratios are considered overvalued.

Oragenics has a net margin of -436.62% compared to Sutro Biopharma's net margin of --. Sutro Biopharma's return on equity of -322.47% beat Oragenics's return on equity of --.

Sutro Biopharma has a consensus price target of $3.26, signalling upside risk potential of 307.65%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 759.69%. Given that Oragenics has higher upside potential than Sutro Biopharma, analysts believe Oragenics is more attractive than Sutro Biopharma.

Sutro Biopharma has a beta of 1.699, which suggesting that the stock is 69.868% more volatile than S&P 500. In comparison Oragenics has a beta of 0.938, suggesting its less volatile than the S&P 500 by 6.243%.

Sutro Biopharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sutro Biopharma pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

Sutro Biopharma quarterly revenues are $17.4M, which are larger than Oragenics quarterly revenues of --. Sutro Biopharma's net income of -$76M is lower than Oragenics's net income of -$2.2M. Notably, Sutro Biopharma's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sutro Biopharma is 0.99x versus 1.12x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -436.62% compared to Sutro Biopharma's net margin of --. Sutro Biopharma's return on equity of -322.47% beat Theriva Biologics's return on equity of --.

Sutro Biopharma has a consensus price target of $3.26, signalling upside risk potential of 307.65%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1490.19%. Given that Theriva Biologics has higher upside potential than Sutro Biopharma, analysts believe Theriva Biologics is more attractive than Sutro Biopharma.

Sutro Biopharma has a beta of 1.699, which suggesting that the stock is 69.868% more volatile than S&P 500. In comparison Theriva Biologics has a beta of 0.848, suggesting its less volatile than the S&P 500 by 15.165%.

Sutro Biopharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sutro Biopharma pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Sutro Biopharma quarterly revenues are $17.4M, which are larger than Theriva Biologics quarterly revenues of --. Sutro Biopharma's net income of -$76M is lower than Theriva Biologics's net income of -$4.3M. Notably, Sutro Biopharma's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sutro Biopharma is 0.99x versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.